Response Genetics starts researching pancreatic cancer test:
This article was originally published in Clinica
Executive Summary
Response Genetics has initiated a two-year research study geared towards the development of a diagnostic test kit for pancreatic cancer. Los Angeles, California-based Response Genetics' technologies enable the extraction and analysis of genetic information from genes derived from formalin-fixed and paraffin embedded tumour samples. This information can be combined with patient outcomes data to aid in the development of assays and diagnostic tests for pancreatic cancer. The study will be conducted in collaboration with the University of California at San Francisco (UCSF), which will provide the tissue samples. According to the American Cancer Society, 33,370 US citizens will die from pancreatic cancer this year, with around 37,170 new cases being diagnosed in the US.
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.